BSW Wealth Partners decreased its holdings in shares of Pfizer Inc. (NYSE:PFE – Free Report) by 4.8% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 55,153 shares of the biopharmaceutical company’s stock after selling 2,807 shares during the quarter. BSW Wealth Partners’ holdings in Pfizer were worth $2,250,000 as of its most recent SEC filing.
Other hedge funds have also bought and sold shares of the company. BancFirst Trust & Investment Management raised its stake in shares of Pfizer by 2.3% in the first quarter. BancFirst Trust & Investment Management now owns 17,794 shares of the biopharmaceutical company’s stock valued at $719,000 after acquiring an additional 398 shares during the period. Strategic Investment Advisors MI raised its stake in shares of Pfizer by 32.1% in the first quarter. Strategic Investment Advisors MI now owns 94,117 shares of the biopharmaceutical company’s stock valued at $3,840,000 after acquiring an additional 22,879 shares during the period. State of Michigan Retirement System raised its stake in shares of Pfizer by 0.9% in the first quarter. State of Michigan Retirement System now owns 1,771,584 shares of the biopharmaceutical company’s stock valued at $72,281,000 after acquiring an additional 15,900 shares during the period. MainStreet Investment Advisors LLC raised its stake in shares of Pfizer by 1.6% in the first quarter. MainStreet Investment Advisors LLC now owns 197,477 shares of the biopharmaceutical company’s stock valued at $8,057,000 after acquiring an additional 3,099 shares during the period. Finally, Center For Asset Management LLC increased its stake in Pfizer by 28.0% in the 1st quarter. Center For Asset Management LLC now owns 23,894 shares of the biopharmaceutical company’s stock worth $975,000 after buying an additional 5,228 shares during the period. Institutional investors own 68.05% of the company’s stock.
Wall Street Analysts Forecast Growth
Several research firms recently commented on PFE. StockNews.com began coverage on shares of Pfizer in a research note on Thursday, August 17th. They issued a “hold” rating on the stock. JPMorgan Chase & Co. reduced their price target on shares of Pfizer from $45.00 to $41.00 and set a “neutral” rating on the stock in a research note on Monday, July 17th. Barclays reduced their price target on shares of Pfizer from $40.00 to $38.00 in a research note on Tuesday, July 11th. Jefferies Financial Group reduced their price target on shares of Pfizer from $40.00 to $38.00 in a research note on Wednesday, August 2nd. Finally, Truist Financial cut their target price on shares of Pfizer from $64.00 to $62.00 and set a “buy” rating on the stock in a research report on Wednesday, August 2nd. Twelve investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $46.35.
Pfizer Stock Down 0.9 %
NYSE:PFE opened at $33.94 on Tuesday. Pfizer Inc. has a fifty-two week low of $33.54 and a fifty-two week high of $54.93. The stock has a market capitalization of $191.62 billion, a P/E ratio of 9.03, a P/E/G ratio of 1.14 and a beta of 0.59. The company has a debt-to-equity ratio of 0.62, a quick ratio of 1.82 and a current ratio of 2.12. The company’s 50-day simple moving average is $35.95 and its 200-day simple moving average is $38.14.
Pfizer (NYSE:PFE – Get Free Report) last released its earnings results on Tuesday, August 1st. The biopharmaceutical company reported $0.67 EPS for the quarter, topping analysts’ consensus estimates of $0.57 by $0.10. The company had revenue of $12.73 billion during the quarter, compared to analysts’ expectations of $13.36 billion. Pfizer had a net margin of 27.55% and a return on equity of 28.36%. Pfizer’s revenue for the quarter was down 54.1% on a year-over-year basis. During the same period last year, the business earned $2.04 EPS. On average, equities analysts anticipate that Pfizer Inc. will post 3.33 earnings per share for the current fiscal year.
Pfizer Dividend Announcement
The business also recently announced a quarterly dividend, which was paid on Tuesday, September 5th. Investors of record on Friday, July 28th were paid a $0.41 dividend. This represents a $1.64 dividend on an annualized basis and a yield of 4.83%. The ex-dividend date was Thursday, July 27th. Pfizer’s dividend payout ratio (DPR) is presently 43.62%.
Pfizer Profile
Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.
Further Reading
- Five stocks we like better than Pfizer
- What Are the FAANG Stocks and Are They Good Investments?
- An Electrifying New Upgrade for Tesla Leads the Market Higher
- How to Use Stock Screeners to Find Stocks
- Oil Jumps, 2 Plastic Stocks About To Become Value Plays
- The How and Why of Investing in Biotech Stocks
- The Top 5 Analysts Calls in September
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE – Free Report).
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.
